What Chrono Therapeutics does

Chrono Therapeutics is a private, Hayward, California-based therapeutics company founded in 2004 by Guy DiPierro with the stated mission to cause a paradigm shift in the way addictions and diseases are treated. The company operates in the chronotherapy / digital therapeutics space, applying timed therapeutic delivery to substance use disorders and chronic disease indications — an approach that implies combination drug-device or regulated digital therapeutic mechanics, though no specific product, dosing regimen, or platform architecture is disclosed in the available data. As of the input, Chrono Therapeutics employs 11-50 staff and maintains a website (chronothera.com) that currently displays only a loading/verification page with no commercial content, product catalog, pricing, or distribution information.

Between 2014 and 2016, Chrono Therapeutics raised approximately $82.5 million across five funding events, including a $32 million Series B in June 2014 led by 5AM Ventures and Canaan Partners and a $47.6 million Series B in September 2016 led by Kaiser Permanente Ventures. The investor syndicate is heavily skewed toward clinical and strategic healthcare: 5AM Ventures, Canaan Partners, Fountain Healthcare Partners, GE Ventures, Mayo Clinic, Cota Capital, Emergent Medical Partners, Endeavour Vision, Mission Bay Capital, Xeraya Capital, Hikma Ventures, Asahi Kasei, and Kaiser Permanente Ventures, plus non-dilutive support from the National Institutes of Health ($2.3 million in August 2015) and Rock Health / MedCity News ($100,000 in March 2015). No revenue, customer base, go-to-market motion, or pricing model is disclosed. The combination of a strategic-pharma/providermix, NIH non-dilutive funding, and the absence of any disclosed commercial product indicates a clinical- and regulatory-stage company pre-commercialization, targeting highly regulated addiction and chronic disease therapeutics.

Name

Chrono Therapeutics

Legal name

Chrono Therapeutics

Website

https://chronothera.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Chrono Therapeutics is a private Hayward, California-based therapeutics company founded in 2004 that develops chronotherapy-based treatments for addictions and chronic diseases, backed by roughly $82.5M from healthcare-specialist and pharma-strategic investors including Kaiser Permanente Ventures, 5AM Ventures, and Mayo Clinic.

Ownership category

akta.pro rank

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Core offering

Chrono Therapeutics develops therapeutic products aimed at treating addictions and diseases, with a stated mission to cause a paradigm shift in how these conditions are addressed. The company combines pharmaceutical and medical-device approaches, supported by strategic investments from healthcare systems and life-sciences venture investors.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Direct peers

• Indivior: Specialty pharma focused on addiction therapeutics, including opioid use disorder and substance use disorders. Directly comparable to Chrono Therapeutics given its CNS/addiction commercial focus and pharmaceutical preparation-based delivery model.
• Alkermes: CNS-focused specialty pharma with marketed addiction and psychiatry products (e.g., Vivitrol for alcohol/opioid dependence). Highly comparable business model and therapeutic-area overlap.
• US WorldMeds: Specialty pharma focused on CNS and addiction therapeutics, including treatments for opioid overdose and substance use disorder. Closely comparable business model and addiction therapeutic-area focus to Chrono Therapeutics.

Emerging players

• Pear Therapeutics: Developed prescription digital therapeutics for substance use disorder and other CNS indications (reSET, reSET-O). Closely comparable addiction focus with a differentiated delivery mechanism, providing a relevant precedent for Chrono's technology-anchored addiction strategy.
• BioXcel Therapeutics: Clinical-stage CNS specialty pharma developing therapeutics for agitation, schizophrenia, and other neuropsychiatric conditions. Comparable as a similarly-sized, privately/founder-aligned CNS biotech pursuing a differentiated delivery or mechanism thesis.
• Intra-Cellular Therapies: CNS-focused pharma with commercialized psychiatry product (Caplyta) and additional neurology pipeline. Comparable as a CNS specialty pharma that scaled from small private status to commercial launch in psychiatry/adjacent CNS indications.

Broad incumbents

• Pfizer (Chantix/varenicline franchise): Markets Chantix (varenicline), a leading prescription smoking-cessation therapy, and is a large diversified pharma with addiction-related R&D. Relevant as the dominant branded incumbent in smoking cessation and a likely strategic acquirer of differentiated niche assets.
• Otsuka Pharmaceutical: Major CNS/addiction pharma with products such as Abilify and involvement in substance use disorder programs. Relevant comparable as a large-pharma acquirer/partner with deep addiction CNS franchise and track record of in-licensing niche assets.
• Hikma Pharmaceuticals: Diversified specialty/generic pharma with CNS and addiction-related products. Relevant as a portfolio investor (Hikma Ventures is a Chrono investor) and as a strategic acquirer/in-licensor of niche CNS assets.

Others

• GlaxoSmithKline (Nicorette/NRT portfolio): Owner of the Nicorette nicotine replacement therapy line and broader consumer-health smoking-cessation portfolio. Comparable as the dominant OTC nicotine-replacement incumbent that any chrono-delivered NRT-style asset would compete against commercially.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/chronothera
• LinkedInlinkedin.com/company/chrono-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chrono Therapeutics